Breast cancer panel halves turnaround time
Answers from the Lab
National guidelines recommend testing for genetic mutations in breast cancer to quickly guide care decisions. In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.
"This panel has been carefully designed to balance clinical utility, diagnostic yields, and future-proofing to generate the most impactful genetic testing results," Dr. Shen says. "The average turnaround time about 10 days, whereas the standard time is typically three weeks."
The next generation sequencing panel includes 11 genes in alignment with NCCN guidelines, and covers both high-risk and moderate-risk genes, to avoid reflex testing. The panel is designed for patients with a breast cancer diagnosis when genetic testing can affect decisions about surgery, targeted therapies, and screening.
"Mayo Clinic's broad expertise and integrated practice allow us to offer a one-stop shop to clinicians," Dr. Shen says. "We have a dedicated team of genetic counselors who can assist clinicians in determining the most appropriate genetic test based on the needs of their patients, and also help providers understand test results."
Listen to learn more about Mayo Clinic Laboratories' rapid breast cancer panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Analytic time: 10-14 days
Days performed: varies
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.